Next 10 |
2024-04-04 17:56:46 ET Summary Akebia Therapeutics, Inc.'s drug Vadadustat, known as Vafseo, received FDA approval for the treatment of anemia in adults on dialysis, offering improved anemia management for a large patient population. The company's other FDA-approved drug, Auryxia,...
2024-04-02 06:16:12 ET Summary Akebia's Vafseo, a HIF-PH inhibitor for DD-CKD anemia, faces skepticism despite FDA approval due to safety concerns. Market skepticism towards HIF-PH inhibitors, evidenced by GSK's hesitance in Europe, suggests limited adoption for Vafseo. Akebia...
2024-03-28 14:00:02 ET Ed Arce from H.C. Wainwright issued a price target of $6.00 for AKBA on 2024-03-28 12:08:00. The adjusted price target was set to $6.00. At the time of the announcement, AKBA was trading at $1.98. The overall price target consensus is at $7.00 with...
2024-03-28 13:30:02 ET H.C. Wainwright analyst issues BUY recommendation for AKBA on March 28, 2024 12:08PM ET. The previous analyst recommendation was Buy. AKBA was trading at $2.0093 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...
Akebia Therapeutics, Inc. (NASDAQ: AKBA) is one today's most active stocks by volume. So far today, approximately 31.95M shares of Akebia Therapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 4.98M shares. Akebia Therapeutics, Inc., a biopharmaceutical company, foc...
A look at the top 10 most actives in the United States Akanda Corp. (AKAN) rose 54.8% to $0.2552 on volume of 35,107,796 shares Nikola Corporation (NKLA) rose 5.0% to $0.9546 on volume of 25,515,019 shares Biodexa Pharmaceuticals plc (BDRX) rose 83.9% to $1.58 on volume of 24,185,655 shar...
2024-03-28 09:20:29 ET DENVER, Colo., Mar 28, 2024 ( 247marketnews.com )- This morning’s notable listings with recent news include Treasure & Shipwreck Recovery (OTCPK: BLIS ), Akebia Therapeutics, Inc. (NASDAQ: AKBA ), Avalo Therapeutics, Inc. (NASDAQ: AV...
2024-03-28 07:21:49 ET DENVER, Colo., Mar 28, 2024 ( 247marketnews.com )- Akebia Therapeutics, Inc. (NASDAQ: AKBA ) announced, last night, that the U.S. Food and Drug Administration approved Vafseo (vadadustat) Tablets, which is now approved in 37 countries, for the treatment of ane...
2024-03-28 05:42:57 ET Akebia Therapeutics ( NASDAQ: AKBA ) shares surged over 25% premarket on Thursday after the U.S. Food and Drug Administration (FDA) approved its Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adult patients o...
2024-03-28 05:41:26 ET More on related stocks RH (RH) Q4 2023 Earnings Call Transcript RH: Q4 Earnings, Improved Results May Be Coming, But Are Likely Priced In MillerKnoll, Inc. (MLKN) Q3 2024 Earnings Call Transcript Intuitive Machines files to sell $300M c...
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
2024-03-28 14:00:02 ET Ed Arce from H.C. Wainwright issued a price target of $6.00 for AKBA on 2024-03-28 12:08:00. The adjusted price target was set to $6.00. At the time of the announcement, AKBA was trading at $1.98. The overall price target consensus is at $7.00 with...
Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (C...
2024-03-28 13:30:02 ET H.C. Wainwright analyst issues BUY recommendation for AKBA on March 28, 2024 12:08PM ET. The previous analyst recommendation was Buy. AKBA was trading at $2.0093 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...